• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

抗氧化剂可减轻层粘连蛋白α2链缺陷型肌营养不良小鼠模型中的肌营养不良症状。

Antioxidants Reduce Muscular Dystrophy in the Mouse Model of Laminin α2 Chain-Deficient Muscular Dystrophy.

作者信息

Harandi Vahid M, Oliveira Bernardo Moreira Soares, Allamand Valérie, Friberg Ariana, Fontes-Oliveira Cibely C, Durbeej Madeleine

机构信息

Unit of Muscle Biology, Department of Experimental Medical Science, Lund University, 221 84 Lund, Sweden.

Functional Genomics & Metabolism Unit, Department of Biochemistry & Molecular Biology, University of Southern Denmark, 5230 Odense, Denmark.

出版信息

Antioxidants (Basel). 2020 Mar 18;9(3):244. doi: 10.3390/antiox9030244.

DOI:10.3390/antiox9030244
PMID:32197453
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7139799/
Abstract

Congenital muscular dystrophy with laminin α2 chain-deficiency (LAMA2-CMD) is a severe neuromuscular disorder without a cure. Using transcriptome and proteome profiling as well as functional assays, we previously demonstrated significant metabolic impairment in skeletal muscle from LAMA2-CMD patients and mouse models. Reactive oxygen species (ROS) increase when oxygen homeostasis is not maintained and, here, we investigate whether oxidative stress indeed is involved in the pathogenesis of LAMA2-CMD. We also analyze the effects of two antioxidant molecules, N-acetyl-L-cysteine (NAC) and vitamin E, on disease progression in the mouse model of LAMA2-CMD. We demonstrate increased ROS levels in LAMA2-CMD mouse and patient skeletal muscle. Furthermore, NAC treatment (150 mg/kg IP for 6 days/week for 3 weeks) led to muscle force loss prevention, reduced central nucleation and decreased the occurrence of apoptosis, inflammation, fibrosis and oxidative stress in LAMA2-CMD muscle. In addition, vitamin E (40 mg/kg oral gavage for 6 days/week for 2 weeks) improved morphological features and reduced inflammation and ROS levels in skeletal muscle. We suggest that NAC and to some extent vitamin E might be potential future supportive treatments for LAMA2-CMD as they improve numerous pathological hallmarks of LAMA2-CMD.

摘要

先天性肌营养不良伴层粘连蛋白α2链缺乏症(LAMA2-CMD)是一种无法治愈的严重神经肌肉疾病。我们之前通过转录组和蛋白质组分析以及功能测定,证明了LAMA2-CMD患者和小鼠模型的骨骼肌存在明显的代谢障碍。当氧稳态无法维持时,活性氧(ROS)会增加,在此,我们研究氧化应激是否确实参与了LAMA2-CMD的发病机制。我们还分析了两种抗氧化分子N-乙酰-L-半胱氨酸(NAC)和维生素E对LAMA2-CMD小鼠模型疾病进展的影响。我们证明LAMA2-CMD小鼠和患者的骨骼肌中ROS水平升高。此外,NAC治疗(腹腔注射150 mg/kg,每周6天,共3周)可预防肌肉力量丧失,减少中央核化,并减少LAMA2-CMD肌肉中凋亡、炎症、纤维化和氧化应激的发生。此外,维生素E(口服灌胃40 mg/kg,每周6天,共2周)改善了骨骼肌的形态特征,降低了炎症和ROS水平。我们认为,NAC以及在一定程度上维生素E可能是未来LAMA2-CMD的潜在支持性治疗方法,因为它们改善了LAMA2-CMD的许多病理特征。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/55d6/7139799/183ac9d7fa7b/antioxidants-09-00244-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/55d6/7139799/eee226f38ce1/antioxidants-09-00244-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/55d6/7139799/86d3f4f634cf/antioxidants-09-00244-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/55d6/7139799/f0146068f935/antioxidants-09-00244-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/55d6/7139799/ed3791b65193/antioxidants-09-00244-g004a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/55d6/7139799/58d36a6d1839/antioxidants-09-00244-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/55d6/7139799/65846f081a42/antioxidants-09-00244-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/55d6/7139799/183ac9d7fa7b/antioxidants-09-00244-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/55d6/7139799/eee226f38ce1/antioxidants-09-00244-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/55d6/7139799/86d3f4f634cf/antioxidants-09-00244-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/55d6/7139799/f0146068f935/antioxidants-09-00244-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/55d6/7139799/ed3791b65193/antioxidants-09-00244-g004a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/55d6/7139799/58d36a6d1839/antioxidants-09-00244-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/55d6/7139799/65846f081a42/antioxidants-09-00244-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/55d6/7139799/183ac9d7fa7b/antioxidants-09-00244-g007.jpg

相似文献

1
Antioxidants Reduce Muscular Dystrophy in the Mouse Model of Laminin α2 Chain-Deficient Muscular Dystrophy.抗氧化剂可减轻层粘连蛋白α2链缺陷型肌营养不良小鼠模型中的肌营养不良症状。
Antioxidants (Basel). 2020 Mar 18;9(3):244. doi: 10.3390/antiox9030244.
2
Effects of metformin on congenital muscular dystrophy type 1A disease progression in mice: a gender impact study.二甲双胍对 1A 型先天性肌营养不良症小鼠疾病进展的影响:一项性别影响研究。
Sci Rep. 2018 Nov 2;8(1):16302. doi: 10.1038/s41598-018-34362-2.
3
Laminin α1 reduces muscular dystrophy in dy mice.层粘连蛋白α1 可减少 dy 小鼠的肌肉萎缩。
Matrix Biol. 2018 Sep;70:36-49. doi: 10.1016/j.matbio.2018.02.024. Epub 2018 Mar 12.
4
Exploratory Profiling of Urine MicroRNAs in the Mouse Model of LAMA2-CMD: Relation to Disease Progression.层粘连蛋白α2链相关先天性肌营养不良(LAMA2-CMD)小鼠模型中尿液微小RNA的探索性分析:与疾病进展的关系
PLoS Curr. 2018 Aug 27;10:ecurrents.md.d0c203c018bc024f2f4c9791ecb05f88. doi: 10.1371/currents.md.d0c203c018bc024f2f4c9791ecb05f88.
5
A Family of Laminin α2 Chain-Deficient Mouse Mutants: Advancing the Research on LAMA2-CMD.一组层粘连蛋白α2链缺陷型小鼠突变体:推进对LAMA2型先天性肌营养不良症的研究
Front Mol Neurosci. 2020 Apr 21;13:59. doi: 10.3389/fnmol.2020.00059. eCollection 2020.
6
Improvement of motor conduction velocity in hereditary neuropathy of LAMA2-CMD dy/dy mouse model by glatiramer acetate.用醋酸格拉替雷改善 LAMA2-CMD 杂合子突变型遗传性运动感觉神经病小鼠模型的运动神经传导速度。
Clin Neurophysiol. 2019 Oct;130(10):1988-1994. doi: 10.1016/j.clinph.2019.07.029. Epub 2019 Aug 16.
7
Human laminin-111 and laminin-211 protein therapy prevents muscle disease progression in an immunodeficient mouse model of LAMA2-CMD.人层粘连蛋白-111和层粘连蛋白-211蛋白疗法可预防LAMA2型先天性肌营养不良免疫缺陷小鼠模型中的肌肉疾病进展。
Skelet Muscle. 2020 Jun 4;10(1):18. doi: 10.1186/s13395-020-00235-4.
8
Current understanding and treatment of cardiac and skeletal muscle pathology in laminin-α2 chain-deficient congenital muscular dystrophy.层粘连蛋白-α2链缺陷型先天性肌营养不良中心脏和骨骼肌病理的当前认识与治疗
Appl Clin Genet. 2019 Jul 3;12:113-130. doi: 10.2147/TACG.S187481. eCollection 2019.
9
Absence of microRNA-21 does not reduce muscular dystrophy in mouse models of LAMA2-CMD.在LAMA2型先天性肌营养不良小鼠模型中,缺失微小RNA-21并不会减轻肌肉萎缩。
PLoS One. 2017 Aug 3;12(8):e0181950. doi: 10.1371/journal.pone.0181950. eCollection 2017.
10
Lama1 upregulation prolongs the lifespan of the dy/dy mouse model of LAMA2-related congenital muscular dystrophy.层粘连蛋白α1(Lama1)的上调延长了与层粘连蛋白α2(LAMA2)相关的先天性肌营养不良的dy/dy小鼠模型的寿命。
J Genet Genomics. 2024 Oct;51(10):1066-1078. doi: 10.1016/j.jgg.2024.05.005. Epub 2024 May 21.

引用本文的文献

1
The protective effect of coadministration of coenzyme Q10 and vitamin E on myopathy induced by simvastatin in rats.辅酶Q10与维生素E联合给药对大鼠辛伐他汀诱导的肌病的保护作用。
Toxicol Rep. 2025 Jan 31;14:101942. doi: 10.1016/j.toxrep.2025.101942. eCollection 2025 Jun.
2
Multi-omics approaches for biomarker discovery and precision diagnosis of prediabetes.用于糖尿病前期生物标志物发现和精准诊断的多组学方法。
Front Endocrinol (Lausanne). 2025 Mar 14;16:1520436. doi: 10.3389/fendo.2025.1520436. eCollection 2025.
3
Model organisms for investigating the functional involvement of NRF2 in non-communicable diseases.

本文引用的文献

1
Randomized controlled trial of -acetylcysteine therapy for -related myopathies.-乙酰半胱氨酸治疗相关肌病的随机对照试验。
Neurology. 2020 Mar 31;94(13):e1434-e1444. doi: 10.1212/WNL.0000000000008872. Epub 2020 Jan 15.
2
Overview on the Effects of -Acetylcysteine in Neurodegenerative Diseases.乙酰半胱氨酸在神经退行性疾病中的作用概述。
Molecules. 2018 Dec 13;23(12):3305. doi: 10.3390/molecules23123305.
3
Exploratory Profiling of Urine MicroRNAs in the Mouse Model of LAMA2-CMD: Relation to Disease Progression.层粘连蛋白α2链相关先天性肌营养不良(LAMA2-CMD)小鼠模型中尿液微小RNA的探索性分析:与疾病进展的关系
用于研究NRF2在非传染性疾病中功能作用的模式生物。
Redox Biol. 2025 Feb;79:103464. doi: 10.1016/j.redox.2024.103464. Epub 2024 Dec 16.
4
Laminin-α2 chain deficiency in skeletal muscle causes dysregulation of multiple cellular mechanisms.层粘连蛋白-α2 链缺陷导致骨骼肌中多个细胞机制失调。
Life Sci Alliance. 2024 Oct 8;7(12). doi: 10.26508/lsa.202402829. Print 2024 Dec.
5
Pharmacological Treatments and Therapeutic Targets in Muscle Dystrophies Generated by Alterations in Dystrophin-Associated Proteins.药物治疗和治疗靶点在肌肉营养不良症中的变化与肌营养不良蛋白相关蛋白。
Medicina (Kaunas). 2024 Jun 27;60(7):1060. doi: 10.3390/medicina60071060.
6
Pharmacotherapeutic Approaches to Treatment of Muscular Dystrophies.肌肉萎缩症的药物治疗方法。
Biomolecules. 2023 Oct 17;13(10):1536. doi: 10.3390/biom13101536.
7
Merosin-deficient congenital muscular dystrophy type 1a: detection of variants in Vietnamese patients.1a型缺乏merosin的先天性肌营养不良症:越南患者中变异体的检测
Front Genet. 2023 Jun 14;14:1183663. doi: 10.3389/fgene.2023.1183663. eCollection 2023.
8
Mechanisms of Myofibre Death in Muscular Dystrophies: The Emergence of the Regulated Forms of Necrosis in Myology.肌肉疾病中肌纤维死亡的机制:肌肉坏死的调控形式的出现。
Int J Mol Sci. 2022 Dec 26;24(1):362. doi: 10.3390/ijms24010362.
9
Linking Oxidative Stress and DNA Damage to Changes in the Expression of Extracellular Matrix Components.将氧化应激和DNA损伤与细胞外基质成分表达的变化相联系。
Front Genet. 2021 Jul 29;12:673002. doi: 10.3389/fgene.2021.673002. eCollection 2021.
10
Natural history, outcome measures and trial readiness in LAMA2-related muscular dystrophy and SELENON-related myopathy in children and adults: protocol of the LAST STRONG study.儿童和成人中 LAMA2 相关肌营养不良症和 SELENON 相关肌病的自然病史、结局指标和临床试验准备情况:LAST STRONG 研究方案。
BMC Neurol. 2021 Aug 12;21(1):313. doi: 10.1186/s12883-021-02336-z.
PLoS Curr. 2018 Aug 27;10:ecurrents.md.d0c203c018bc024f2f4c9791ecb05f88. doi: 10.1371/currents.md.d0c203c018bc024f2f4c9791ecb05f88.
4
Effects of metformin on congenital muscular dystrophy type 1A disease progression in mice: a gender impact study.二甲双胍对 1A 型先天性肌营养不良症小鼠疾病进展的影响:一项性别影响研究。
Sci Rep. 2018 Nov 2;8(1):16302. doi: 10.1038/s41598-018-34362-2.
5
N-acetyl cysteine alleviates oxidative stress and protects mice from dilated cardiomyopathy caused by mutations in nuclear A-type lamins gene.N-乙酰半胱氨酸可减轻氧化应激,保护核 A 型层粘连蛋白基因突变小鼠免于扩张型心肌病。
Hum Mol Genet. 2018 Oct 1;27(19):3353-3360. doi: 10.1093/hmg/ddy243.
6
At the Crossroads of Clinical and Preclinical Research for Muscular Dystrophy-Are We Closer to Effective Treatment for Patients?在肌肉萎缩症的临床前和临床研究的十字路口——我们离为患者提供有效治疗更近了吗?
Int J Mol Sci. 2018 May 16;19(5):1490. doi: 10.3390/ijms19051490.
7
Natural disease history of the dy2J mouse model of laminin α2 (merosin)-deficient congenital muscular dystrophy. laminin α2 (merosin)-deficient 先天性肌营养不良症 dy2J 小鼠模型的自然病史。
PLoS One. 2018 May 15;13(5):e0197388. doi: 10.1371/journal.pone.0197388. eCollection 2018.
8
Exploratory Application of Neuropharmacometabolomics in Severe Childhood Traumatic Brain Injury.神经药理代谢组学在儿童严重创伤性脑损伤中的探索性应用。
Crit Care Med. 2018 Sep;46(9):1471-1479. doi: 10.1097/CCM.0000000000003203.
9
Oxidative stress, aging, and diseases.氧化应激、衰老和疾病。
Clin Interv Aging. 2018 Apr 26;13:757-772. doi: 10.2147/CIA.S158513. eCollection 2018.
10
Increased polyamines as protective disease modifiers in congenital muscular dystrophy.多胺作为先天性肌营养不良症的保护性疾病修饰剂增加。
Hum Mol Genet. 2018 Jun 1;27(11):1905-1912. doi: 10.1093/hmg/ddy097.